development expertise
to help your business grow.

Bringing new products to market is often a lengthy and bureaucratic process. To give you fast and easy access to international markets, we provide all-inclusive and hassle-free licensing for high-quality, self-developed transdermal patches.

Licensing models for rapid growth

As a trusted partner to many high-profile pharmaceutical companies, we offer an all-inclusive licensing package for our transdermal patches. Licenses are granted to sell these products in regions where the relevant active substances have already been approved. We do not license products that are still in our development pipeline. Our partners are responsible for all marketing activities in the target markets, while we manufacture the patches and handle all patent and regulatory issues as the rights holder.

Our licensing services:

  • Provision of approved products
  • Dossiers for global applications based on the EU dossier
  • Production of high-quality pharmaceuticals on state-of-the-art production lines
  • Market-specific packaging of products via high-capacity packaging lines
  • Continuous lifecycle management with marketing authorization maintenance and ongoing process improvement

Licensable products

The following Luye Pharma products are currently available for licensing. If you are interested in other products, please contact us. If the product you need is not already part of our development program, we can arrange a contract development model that suits your needs.


  • Indication: moderate to severe cancer-related pain and severe pain unresponsive to non-opioid analgesics
  • Dosage strengths: 35, 52.5 and 70 μg/h
  • Application period: 3 days


  • Indication: strong chronic pain requiring continuous, long-term opioid analgesia
  • Dosage strengths: 12.5, 25, 50, 75 and 100 μg/h
  • Application period: 3 days

Rivastigmine Single Day

  • Indication: mild to moderate dementia from Alzheimer’s or Parkinson’s disease
  • Dosage strengths: 4.6, 9.5 and 13.3 mg/24h
  • Application period: 1 day

Rivastigmine Multi Day

  • Indication: mild to moderate dementia from Alzheimer’s or Parkinson’s disease
  • Dosage strengths: 4.6 and 9.5 mg/24h
  • Application period: 3 - 4 days

Note: The products listed here are available for licensing in countries where their sale does not infringe on third-party rights.